Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group
Por:
del Alcazar, E, Suarez-Perez, JA, Armesto, S, Rivera, R, Herrera-Acosta, E, Herranz, P, Martin, I, Montesinos, E, Hospital, M, Vilarrasa, E, Ferran, M, Ruiz-Villaverde, R, Sahuquillo-Torralba, A, Ruiz-Genao, DP, Perez-Barrio, S, Munoz, C, Llamas, M, Valenti, F, Mitxelena, MJ, Lopez-Ferrer, A, Carretero, G, Vidal, D, Mollet, J, Belinchon, I, Carrascosa, JM
Publicada:
1 dic 2020
Ahead of Print:
1 jun 2020
Resumen:
Background Little has been published on the real-world effectiveness and safety of apremilast in psoriasis.
Objectives To evaluate the effectiveness, safety and drug survival of apremilast at 52 weeks in patients with moderate to severe plaque psoriasis or palmoplantar psoriasis in routine clinical practice.
Methods Retrospective, multicentre study of adult patients with moderate to severe plaque psoriasis or palmoplantar psoriasis treated with apremilast from March 2016 to March 2018.
Results We studied 292 patients with plaque psoriasis and 85 patients with palmoplantar psoriasis. The mean (SD) Psoriasis Area and Severity Index (PASI) score was 10.7 (7.0) at baseline and 3.0 (4.2) at 52 weeks. After 12 months of treatment, 73.6% of patients had a PASI score of 3 or less. In terms of relative improvement by week 52, 49.7% of patients achieved PASI-75 (>= 75% reduction in PASI score) and 26.5% achieved PASI-90. The mean physician global assessment score for palmoplantar psoriasis fell from 4.2 (5.2) at baseline to 1.3 (1.3) at week 52. Overall drug survival after 1 year of treatment with apremilast was 54.9 %. The main reasons for treatment discontinuation were loss of efficacy (23.9%) and adverse events (15.9%). Almost half of the patients in our series (47%) experienced at least one adverse event. The most common events were gastrointestinal problems.
Conclusions Apremilast may be a suitable alternative for the treatment of moderate to severe psoriasis and palmoplantar psoriasis. Although the drug has a good safety profile, adverse gastrointestinal effects are common.
Filiaciones:
del Alcazar, E:
Univ Autonoma Barcelona UAB, Hosp Univ Germans Trias i Pujol, Dept Dermatol, Badalona, Spain
Suarez-Perez, JA:
Hosp Univ Virgen de la Victoria, Dept Dermatol, Malaga, Spain
Armesto, S:
Hosp Univ Valdecilla, Dept Dermatol, Santander, Spain
Rivera, R:
Hosp Univ 12 Octubre, Dept Dermatol, Madrid, Spain
Herrera-Acosta, E:
Hosp Univ Virgen de la Victoria, Dept Dermatol, Malaga, Spain
Herranz, P:
Hosp Univ La Paz, Dept Dermatol, Madrid, Spain
Martin, I:
Hosp Univ Getafe, Dept Dermatol, Madrid, Spain
Montesinos, E:
Hosp Clin Univ Valencia, Dept Dermatol, Valencia, Spain
Hospital, M:
Hosp Univ Puerta de Hierro Majadahonda, Dept Dermatol, Madrid, Spain
Vilarrasa, E:
Hosp Hosp Santa Creu & St Pau, Dept Dermatol, Barcelona, Spain
Ferran, M:
Hosp del Mar, Dept Dermatol, Inst Mar Invest Med, Barcelona, Spain
Ruiz-Villaverde, R:
Hosp Univ San Cecilio, Dept Dermatol, Granada, Spain
Sahuquillo-Torralba, A:
Hosp Univ & Politecn La Fe, Dept Dermatol, Inst Invest Sanitaria La Fe, Valencia, Spain
Ruiz-Genao, DP:
Hosp Univ Fdn Alcorcon, Dept Dermatol, Madrid, Spain
Perez-Barrio, S:
Hosp Univ Basurto, Dept Dermatol, Bilbao, Spain
Munoz, C:
Hosp Granollers, Dept Dermatol, Granollers, Spain
Llamas, M:
Hosp Univ La Princesa, Dept Dermatol, Madrid, Spain
Valenti, F:
Hosp Univ Bellvitge, Dept Dermatol, Barcelona, Spain
Mitxelena, MJ:
Hosp Univ Navarra, Dept Dermatol, Pamplona, Spain
Lopez-Ferrer, A:
Hosp Hosp Santa Creu & St Pau, Dept Dermatol, Barcelona, Spain
Carretero, G:
Hosp Univ Gran Canaria Doctor Negrin, Dept Dermatol, Las Palmas Gran Canaria, Spain
Vidal, D:
Hosp Moises Broggi, Dept Dermatol, St Joan Despi, Spain
Mollet, J:
Hosp Univ Vall dHebron, Dept Dermatol, Barcelona, Spain
Belinchon, I:
UMH Alicante, Dept Dermatol, Hosp Univ Alicante ISABIAL, Alicante, Spain
Carrascosa, JM:
Univ Autonoma Barcelona UAB, Hosp Univ Germans Trias i Pujol, Dept Dermatol, Badalona, Spain
|